Last reviewed · How we verify
Cilostazol+Probucol
Cilostazol+Probucol is a Antiplatelet agent + Antioxidant lipid-lowering agent Small molecule drug developed by Otsuka Beijing Research Institute. It is currently FDA-approved for Intermittent claudication and peripheral arterial disease, Secondary prevention of atherosclerotic cardiovascular disease. Also known as: Pletaal and Changtai.
Cilostazol inhibits phosphodiesterase-3 to increase cAMP and promote vasodilation and antiplatelet effects, while probucol acts as an antioxidant to reduce lipid peroxidation and improve lipid profiles.
Cilostazol is a small molecule phosphodiesterase 3A inhibitor used in clinical trials for various conditions, including brain ischemia, intracranial hemorrhages, hyperlipidemias, type 2 diabetes mellitus, and arteriosclerosis obliterans. Probucol is also being studied in clinical trials for these conditions, although its exact mechanism of action is not specified in the provided information.
At a glance
| Generic name | Cilostazol+Probucol |
|---|---|
| Also known as | Pletaal and Changtai |
| Sponsor | Otsuka Beijing Research Institute |
| Drug class | Antiplatelet agent + Antioxidant lipid-lowering agent |
| Target | Phosphodiesterase-3 (cilostazol); Antioxidant mechanism (probucol) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Cilostazol is a phosphodiesterase-3 inhibitor that increases intracellular cAMP levels, leading to vasodilation, inhibition of platelet aggregation, and improved blood flow. Probucol is a lipophilic antioxidant that reduces oxidative stress and LDL cholesterol oxidation. The combination targets both platelet dysfunction and lipid-mediated atherosclerosis in cardiovascular disease.
Approved indications
- Intermittent claudication and peripheral arterial disease
- Secondary prevention of atherosclerotic cardiovascular disease
Common side effects
- Headache
- Diarrhea
- Palpitations
- Dizziness
Key clinical trials
- To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject (PHASE4)
- Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker (PHASE4)
- Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety (PHASE2)
- Safety and Pharmacokinetics of Probucol and Cilostazol (PHASE4)
- Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease (PHASE4)
- PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study (PHASE4)
- PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage (PHASE4)
- A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cilostazol+Probucol CI brief — competitive landscape report
- Cilostazol+Probucol updates RSS · CI watch RSS
- Otsuka Beijing Research Institute portfolio CI
Frequently asked questions about Cilostazol+Probucol
What is Cilostazol+Probucol?
How does Cilostazol+Probucol work?
What is Cilostazol+Probucol used for?
Who makes Cilostazol+Probucol?
Is Cilostazol+Probucol also known as anything else?
What drug class is Cilostazol+Probucol in?
What development phase is Cilostazol+Probucol in?
What are the side effects of Cilostazol+Probucol?
What does Cilostazol+Probucol target?
Related
- Drug class: All Antiplatelet agent + Antioxidant lipid-lowering agent drugs
- Target: All drugs targeting Phosphodiesterase-3 (cilostazol); Antioxidant mechanism (probucol)
- Manufacturer: Otsuka Beijing Research Institute — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Intermittent claudication and peripheral arterial disease
- Indication: Drugs for Secondary prevention of atherosclerotic cardiovascular disease
- Also known as: Pletaal and Changtai
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing